FGEN
FibroGen, Inc.
Set alert
9.07 USD 0.00 0.00%
9.02 Day range 9.21
0.18 52-week range 2.93
- YTD
- +3.30%
- 1 year
- -41.90%
- Open
- 9.10
- Prev close
- 9.07
- Mkt cap
- 48.37M
- Vol
- 29.25K
- Avg vol
- 1.21M
- EPS
- -1.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.02
- High
- 9.21
- Forward P/E
- -0.70
- Beta
- 0.73
- Short ratio
- 3.27
- Inst. own
- 55.04%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.35386
- 200-d avg
- 0.852785
- 1y target
- 10.00
Key statistics
- Market cap
- 48.37M
- Enterprise value
- 103.85M
- Trailing P/E
- 0.00
- Forward P/E
- -0.70
- PEG ratio
- 0.00
- Price / sales
- 0.28
- Price / book
- 0.00
- EPS (TTM)
- -1.23
- Beta
- 0.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -96.84%
- Revenue (TTM)
- 173.82M
- Revenue growth
- 14.30%
- Free cash flow
- -121.83M
- Total cash
- 140.71M
- Total debt
- 163.78M
- Return on equity
- 0.00%
- Shares outstanding
- 100.77M
- Short % of float
- 5.07%
- 50-day average
- 0.35386
- 200-day average
- 0.852785
Analyst view
Consensus: hold
Hold
Price target (mean) 10.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.20.
Financials — quick view
FGEN Revenue — quarterly 1.08M
FGEN Net income — quarterly 200.64M
FGEN EPS — quarterly 49.61
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.38 | -0.17 | +0.21 | +55.26% |
| Aug 6, 2024 | Jun 1, 2024 | -0.26 | -0.16 | +0.10 | +38.46% |
| May 6, 2024 | Mar 1, 2024 | -0.31 | -0.33 | -0.02 | -6.45% |
| Feb 26, 2024 | Dec 1, 2023 | -0.42 | -0.57 | -0.15 | -35.71% |
| Nov 6, 2023 | Sep 1, 2023 | -0.68 | -0.52 | +0.16 | +23.53% |
| Aug 7, 2023 | Jun 1, 2023 | -0.72 | -0.65 | +0.07 | +9.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2023 | B of A Securities | down | Neutral | Underperform |
| Jun 27, 2023 | Goldman Sachs | main | Sell | Sell |
| Jun 27, 2023 | Raymond James | down | Outperform | Market Perform |
| Jun 26, 2023 | B of A Securities | down | Buy | Neutral |
| Jun 26, 2023 | Stifel | down | Buy | Hold |
| Jun 26, 2023 | Raymond James | down | Outperform | Market Perform |
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fibrogen.com
News
- Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
- FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
- 12 Health Care Stocks Moving In Monday's After-Market Session
- FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
- FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
- FibroGen to Report Third Quarter 2025 Financial Results
- FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
- FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Your note
Sign in to keep a note on FGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADIB DEYAA | Officer | Purchase | Jun 11, 2024 | 82,123 |
| BLAUG SUZANNE | Director | Sale | Jun 8, 2023 | 29,594 |
| BRENNAN AOIFE M | Director | Sale | Jun 8, 2023 | 27,947 |
| CHUNG CHRISTINE | Officer | Stock Award(Grant) | Mar 5, 2024 | 341,028 |
| CONTERNO ENRIQUE A | Chief Executive Officer | Sale | Jul 6, 2023 | 402,522 |
| CRAVATT BENJAMIN PH.D. | Director | Sale | Jun 8, 2023 | 28,736 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Management Company | 9.84% | 9,911,231 | 4.76M | Sep 29, 2024 |
| Armistice Capital, LLC | 6.75% | 6,800,000 | 3.26M | Sep 29, 2024 |
| Vanguard Group Inc | 5.84% | 5,882,361 | 2.82M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.88% | 3,905,350 | 1.87M | Sep 29, 2024 |
| Blackrock Inc. | 2.37% | 2,391,439 | 1.15M | Sep 29, 2024 |
| 683 Capital Management LLC | 2.12% | 2,138,402 | 1.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Horizon Fund-Capital Opportunity Fund | 3.95% | 3,980,425 | 1.91M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.89% | 2,916,871 | 1.40M | Sep 29, 2024 |
| Primecap Odyssey Aggressive Growth Fund | 2.62% | 2,635,691 | 1.27M | Sep 29, 2024 |
| Primecap Odyssey Growth Fund | 1.56% | 1,567,085 | 752.20K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.37% | 1,380,877 | 662.82K | Sep 29, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.89% | 898,604 | 431.33K | Sep 29, 2024 |